GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Cyclically Adjusted PB Ratio

Genmab A/S (Genmab A/S) Cyclically Adjusted PB Ratio : 8.60 (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Genmab A/S's current share price is $27.77. Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.23. Genmab A/S's Cyclically Adjusted PB Ratio for today is 8.60.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

GMAB' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 8.55   Med: 23.3   Max: 34.31
Current: 8.56

During the past years, Genmab A/S's highest Cyclically Adjusted PB Ratio was 34.31. The lowest was 8.55. And the median was 23.30.

GMAB's Cyclically Adjusted PB Ratio is ranked worse than
87.9% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs GMAB: 8.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab A/S's adjusted book value per share data for the three months ended in Mar. 2024 was $7.272. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.23 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted PB Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.77 29.31 22.44 17.77 10.22

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.57 13.80 12.53 10.22 9.25

Competitive Comparison of Genmab A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PB Ratio falls into.



Genmab A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=27.77/3.23
=8.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Genmab A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.272/118.4000*118.4000
=7.272

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.563 99.700 0.669
201409 0.589 99.700 0.699
201412 0.591 99.400 0.704
201503 0.646 100.200 0.763
201506 0.710 100.300 0.838
201509 0.771 100.200 0.911
201512 0.855 99.800 1.014
201603 0.881 100.200 1.041
201606 0.946 100.600 1.113
201609 0.985 100.200 1.164
201612 1.136 100.300 1.341
201703 1.187 101.200 1.389
201706 1.347 101.200 1.576
201709 1.433 101.800 1.667
201712 1.633 101.300 1.909
201803 1.765 101.700 2.055
201806 1.756 102.300 2.032
201809 1.806 102.400 2.088
201812 1.993 102.100 2.311
201903 2.001 102.900 2.302
201906 2.037 102.900 2.344
201909 2.841 102.900 3.269
201912 3.219 102.900 3.704
202003 3.272 103.300 3.750
202006 4.141 103.200 4.751
202009 4.478 103.500 5.123
202012 4.780 103.400 5.473
202103 4.919 104.300 5.584
202106 5.000 105.000 5.638
202109 5.150 105.800 5.763
202112 5.132 106.600 5.700
202203 5.118 109.900 5.514
202206 5.288 113.600 5.511
202209 5.387 116.400 5.480
202212 5.943 115.900 6.071
202303 5.996 117.300 6.052
202306 6.410 116.400 6.520
202309 6.817 117.400 6.875
202312 7.079 116.700 7.182
202403 7.272 118.400 7.272

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (NAS:GMAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus